Sifalimumab MEDI-545; MDX 1103|cas:1006877-41-3|西域试剂

Sifalimumab MEDI-545; MDX 1103,98.55%

产品编号：Bellancom-P99219| CAS NO：1006877-41-3

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99219	￥3750.00	杭州北京（现货）
Bellancom-P99219	￥9380.00	杭州北京（现货）
Bellancom-P99219	￥15000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Sifalimumab MEDI-545; MDX 1103

产品介绍

Sifalimumab (MEDI-545) 是一种 anti-IFNα 单克隆抗体，通过与多种干扰素-α 亚型结合来抑制异常的免疫活动。Sifalimumab 可用于系统性红斑狼疮 (SLE) 的研究。

生物活性

Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research.

体外研究

Sifalimumab (3-36 μg/well; 72 h) attenuates lymphocyte cytotoxicity co-cultured with U-87MG.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	U-87MG cells and AGS lymphocytes
Concentration:	3-36 μg/well
Incubation Time:	72 hours
Result:	Attenuated lymphocyte cytotoxicity triggered by IFN I (P<0.05).

体内研究
(In Vivo)

Sifalimumab (subcutaneous injection; 30 mg/kg and 3 μg/g) treatment shows therapeutic effect and attenuates the lymphocyte infiltration.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wild-type male BALB/c mice
Dosage:	30 mg/kg and 3 μg/g
Administration:	Subcutaneous injection; 30 mg/kg and 3 μg/g
Result:	Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P < 0.05). Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration. Attenuated the CD45 increase (P<0.05).

体内研究

Sifalimumab (subcutaneous injection; 30 mg/kg and 3 μg/g) treatment shows therapeutic effect and attenuates the lymphocyte infiltration.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wild-type male BALB/c mice
Dosage:	30 mg/kg and 3 μg/g
Administration:	Subcutaneous injection; 30 mg/kg and 3 μg/g
Result:	Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P < 0.05). Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration. Attenuated the CD45 increase (P<0.05).

体内研究

Sifalimumab (subcutaneous injection; 30 mg/kg and 3 μg/g) treatment shows therapeutic effect and attenuates the lymphocyte infiltration.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wild-type male BALB/c mice
Dosage:	30 mg/kg and 3 μg/g
Administration:	Subcutaneous injection; 30 mg/kg and 3 μg/g
Result:	Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P < 0.05). Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration. Attenuated the CD45 increase (P<0.05).